Clinical Trials Logo

Retinopathy of Prematurity clinical trials

View clinical trials related to Retinopathy of Prematurity.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03399825 Withdrawn - Clinical trials for Diabetic Retinopathy

Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age)

OCTAC
Start date: January 2018
Phase:
Study type: Observational

Comparison of OCTA to conventional imaging modalities for the diagnosis of eye diseases in children

NCT ID: NCT02655432 Withdrawn - Cataract Clinical Trials

Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population

POPH
Start date: January 2016
Phase: Phase 0
Study type: Observational

Screening of haitian children between the ages of 3 and 6 years old for amblyogenic risk factors with the use of the Spot photoscreener. The photoscreener results will be compared to the complete ophthalmologic evaluation. Primarily, this will allow evaluation of the performance of the spot photoscreener in the haitian children population. Secondarily, this study will gather epidemiological information on vision problems in the haitian children population.

NCT ID: NCT01470430 Withdrawn - Clinical trials for Retinopathy of Prematurity (ROP)

VEGF In Systemic Circulation Of ROP-infants

Start date: March 2012
Phase: N/A
Study type: Observational

The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular treatment with either intravitreal injections of anti-VEGF agents or retinal laser photocoagulation. The primary aim is to determine if serum VEGF levels change after treatment.

NCT ID: NCT01232777 Withdrawn - Clinical trials for Retinopathy of Prematurity

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

BLOCK-ROP
Start date: June 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a single intravitreal (into the gel of the eye) injection of Avastin 0.625mg or 0.75mg is equivalent (non-inferior) to treatment with standard of care laser in infants with Type I pre-threshold retinopathy of prematurity (ROP) diagnosed at 30-36 weeks gestational age.